Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06488209 · ClinicalTrials.gov registry record · Phase 1
Single and Multiple Ascending Dose Study in Healthy Participants and Participants With an Autoimmune Disease
A Phase 1 study, sponsored by Almirall, S.A..
- Completed
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
NCT06488209 is a Phase 1 study that has completed, run by Almirall, S.A.. The registered enrollment target is 69 participants.
The verdict
NCT06488209, a Phase 1 study, has completed, sponsored by Almirall, S.A..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
Study Summary
The main purpose of this study is to to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity of LAD191 in healthy adults and in adults with an autoimmune disease.
Interventions
- OTHER Placebo
- DRUG LAD191
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2022-07-29 |
| Est. Completion | 2025-04-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06488209
The ClinicalTrials.gov registry entry for NCT06488209 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Almirall, S.A., which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06488209 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06488209 about?
NCT06488209 is a clinical study titled "Single and Multiple Ascending Dose Study in Healthy Participants and Participants With an Autoimmune Disease". The main purpose of this study is to to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity of LAD191 in healthy adults and in adults with an autoimmune disease.
What is the current status of trial NCT06488209?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2022-07-29. Estimated completion is 2025-04-03.
What interventions are being tested in trial NCT06488209?
The interventions under investigation include: Placebo (OTHER), LAD191 (DRUG).
Who is sponsoring clinical trial NCT06488209?
This trial is sponsored by Almirall, S.A., which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.